We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03363893
Recruitment Status : Completed
First Posted : December 6, 2017
Last Update Posted : February 9, 2023
Sponsor:
Information provided by (Responsible Party):
Carrick Therapeutics Limited

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.

Condition or disease Intervention/treatment Phase
Advanced Solid Malignancies Drug: CT7001 Drug: CT7001 in combination with fulvestrant Phase 1 Phase 2

Detailed Description:

Module 1 comprises two sequential parts:

  • Part A: First-in-human (FiH) dose escalation investigating the safety and tolerability of CT7001 to identify the minimum biologically active dose (MBAD) and maximum tolerated dose (MTD). Part A also includes a cohort expansion for breast cancer participants only: this includes sequential tumour biopsies for evaluation of pharmacokinetic (PK), pharmacodynamic (PD) and tumour responses. The module is completed.

  • Part B: To refine the safety, tolerability, and PK and PD profiles of CT7001 monotherapy in participants with advanced solid malignancies from up to four tumour- specific cohorts, which may include, but is not limited to, triple-negative breast cancer, ovarian cancer, small-cell lung cancer and prostate cancer.

    • Part B, Cohort 1, Triple-Negative Breast Cancer (M1B-1 TNBC) treated with CT7001 as monotherapy. The module is completed.
    • Part B, Cohort 2, Prostate Cancer (M1B-2 CRPC) treated with CT7001 as monotherapy. The module is completed.
  • Module 4 is a study investigating the effect of food on the PK of CT7001 monotherapy in participants with advanced solid malignancies. The module is completed.
  • Module 2 is a Phase Ib/II, 3-part safety and efficacy study in participants with hormone-receptor positive (HR+ve) and human epidermal growth factor-2 negative (HER2-ve) breast cancer. This module will dose CT7001 in combination with fulvestrant. Module 2 consists of 3 parts - Part A, Part B and Part C. Module 2 Part A recruitment is completed. Part B is double-blind, randomized and placebo-controlled Part C will be a crossover from Part B. Module 2B/C were planned to be open in 2022 but the modules will not be progressed further.
  • Module 6 is a Phase 1 study to explore the tolerability of, and the total and peak exposure of, an enteric capsule formulation of CT7001 [CT7001(EC)], when given as monotherapy to patients with advanced solid malignancies. Module 6 will not be initiated.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 124 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Modular design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
Actual Study Start Date : November 14, 2017
Actual Primary Completion Date : December 15, 2022
Actual Study Completion Date : December 15, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Fulvestrant

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Module 1 Part A
Participants with advanced solid tumours receive CT7001 (samuraciclib) as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D). This module includes a cohort expansion of participants with breast cancer who provide paired biopsy samples.
 Drug: CT7001
Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Other Name: Samuraciclib
Experimental: Module 1 Part B

Participants with advanced solid tumours that may include, but is not limited to, triple negative breast cancer (TNBC), castrate-resistant prostate cancer (CRPC), small cell lung cancer (SCLC) or ovarian cancer, will receive CT7001 (samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.

To date Module 1 Part B Arm has recruited a cohort of CRPC participants.

 Drug: CT7001
Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Other Name: Samuraciclib
Experimental: Module 1 Part B-1 TNBC Expansion
Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
 Drug: CT7001
Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Other Name: Samuraciclib
Experimental: Module 2 Part A
Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 (samuraciclib) oral monotherapy in combination with fulvestrant.
 Drug: CT7001 in combination with fulvestrant
Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression in combination with fulvestrant given as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter
Other Name: Samuraciclib
Experimental: Module 4
Participants with advanced solid tumours will receive CT7001(samuraciclib) oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.
 Drug: CT7001
Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Other Name: Samuraciclib


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability) [ Time Frame: Screening to end of study ]
    Type, incidence and severity


Secondary Outcome Measures :
  1. Maximum Plasma Concentration of CT7001 (and Fulvestrant, where applicable) (Cmax) [ Time Frame: After the first dose and during the dosing period ]
  2. Area Under the Curve (AUC) [ Time Frame: After the first dose and during the dosing period ]
  3. Biological Activity Parameters (Biomarkers) in Peripheral Blood [ Time Frame: Screening to end of treatment ]
  4. Anti-tumour Activity according to RECIST v1.1 [ Time Frame: Baseline until disease progression or withdrawal from the study ]
  5. Objective Response Rate (ORR) [ Time Frame: Baseline until disease progression or withdrawal from the study ]
  6. Progression-Free Survival (PFS) [ Time Frame: Baseline until disease progression or withdrawal from the study ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Core Inclusion Criteria:

  1. ECOG performance status 0 or 1 with no deterioration over the previous 2 weeks
  2. Estimated life expectancy of greater than 12 weeks
  3. Ability to swallow and retain oral medication
  4. Women either of non-childbearing potential or of childbearing potential willing to practice effective contraception for the duration of the study and for 6 months (Module 1, Module 4) and 24 months (Module 2) after the last dose of CT7001
  5. Sexually active male patients must be willing to use condoms with all sexual partners for the duration of the study and for 3 months after the last dose of CT7001.
  6. Provision of signed and dated, written informed consent

Core Exclusion Criteria:

  1. Any other malignancy that has been active or treated within the past 3 years, with the exception of cervical intraepithelial neoplasia and non-melanoma skin cancer
  2. Any unresolved toxicity (except alopecia) from prior therapy of ≥ CTCAE Grade 2
  3. Spinal cord compression or brain metastases, unless asymptomatic, stable, and not requiring steroids for at least 4 weeks before the first dose of investigational product (IP)
  4. Refractory nausea and vomiting, chronic gastrointestinal (GI) disease or previous significant bowel resection, with clinically significant sequelae that would preclude adequate absorption of CT7001
  5. Uncontrolled seizures
  6. Active infection requiring systemic antibiotic, antifungal, or antiviral medication
  7. Severe or uncontrolled medical condition or psychiatric condition
  8. Active bleeding diatheses
  9. Renal transplant
  10. Known hepatitis B, hepatitis C, or human immunodeficiency virus infection
  11. Breastfeeding or pregnancy
  12. Receipt of systemic cytotoxic treatment for the malignancy within 28 days or ≤ 5 half-lives, whichever is shorter before the first dose of IP
  13. Receipt of non-cytotoxic treatment for the malignancy within 5 half-lives of the drug before the first dose of IP
  14. Receipt of corticosteroids (at a dose > 10 mg prednisone/day or equivalent) within 14 days before the first dose of IP
  15. Receipt of any small-molecule investigational medicinal product (IMP) within 28 days or ≤ 5 half-lives, whichever is shorter before the first dose of IP
  16. Receipt of any biological IMP (e.g., immune checkpoint blockers, antibodies, nanoparticles) within 42 days before the first dose of IP
  17. Receipt of St John's Wort within 21 days before the first dose of IP or of another concomitant medication, herbal supplement, or food that is a strong inhibitor or inducer of CYP3A4, CYP2C19, CYP2D6, or P-glycoprotein (PGP) activity within 14 days before the first dose of CT7001
  18. Receipt of a blood transfusion (blood or blood products) within 14 days before the first dose of IP
  19. Known hypersensitivity to CT7001 or any excipient of the product

  20. Impaired hepatic or renal function as demonstrated by any of the following laboratory values:

    1. Albumin < 30 g/L
    2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × the upper limit of normal (ULN)
    3. > 5.0 × ULN for patients with liver metastases
    4. Total bilirubin > 1.5 × ULN
    5. Serum creatinine > 1.5 × ULN
  21. Liver function deteriorating in a manner that would likely make the participant meet the AST, ALT, or bilirubin levels specified above at the time of the first dose of IP
  22. Other evidence of impaired hepatic synthesis function

  23. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    1. Absolute neutrophil count (ANC) < 1.5 × 10^9/L
    2. Platelet count < 100 × 10^9/L
    3. Haemoglobin < 90 g/L
  24. Persistent (> 4 weeks) severe pancytopenia due to previous therapy rather than to disease (ANC < 0.5 × 10^9/L or platelets < 50 x 10^9/L)
  25. Cardiac dysfunction (defined as myocardial infarction within 6 months of study entry, New York Heart Association Class II/III/IV heart failure, unstable angina, unstable cardiac arrhythmias, or left ventricular ejection fraction < 55 percent)
  26. Mean resting QT interval corrected for heart rate by the Fridericia formula (QTcF) > 470 msec obtained from 3 electrocardiograms (ECGs) obtained within 5 minutes of each other prior to the first dose
  27. Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG (e.g., complete left bundle branch block, third degree heart block). Controlled atrial fibrillation (AF) is permitted
  28. Any factor that increases the risk of QTc prolongation or of arrhythmic events (e.g., heart failure, hypokalaemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death under 40 years of age)
  29. In the opinion of the Investigator, unlikely to comply with study procedures, restrictions, or requirements
  30. A history of haemolytic anaemia or marrow aplasia
  31. Has received a live-virus vaccination within 28 days or less of planned treatment start

Additional Module 1A Inclusion Criteria:

  1. Histological, radiological or cytological confirmation of an advanced non-haematological malignancy not considered to be appropriate for further standard treatment
  2. Module 1A biopsy cohort only : at least one tumour suitable for repeat biopsy

Additional Module 1A Exclusion Criteria:

1. International normalised ratio (INR) ≥1.5

Additional Module 1B Inclusion Criteria

  1. Histological or cytological confirmation of metastasis or locally advanced tumour
  2. At least one line of systemic anti-cancer therapy
  3. Disease measurable by RECIST v1.1

Additional Module 1B-1 (TNBC Expansion) Inclusion Criteria:

  1. Histologically-confirmed carcinoma of breast not expressing oestrogen receptor (ER) or progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2)
  2. Documented disease progression on or within 6 months of most recent cytotoxic prior cytotoxic chemotherapy
  3. Disease measurable by RECIST v1.1
  4. Must have received at least one cytotoxic chemotherapy for metastatic/locally advanced disease

Additional Module 1B-1 (TNBC Expansion) Exclusion Criteria:

  1. No more than three lines of cytotoxic chemotherapy for metastatic/locally advanced disease
  2. No advanced, symptomatic visceral metastases
  3. No known symptomatic central nervous system (CNS) metastases, carcinomatous meningitis or leptomeningeal disease
  4. Prior exposure to CT7001
  5. Patients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Carrick employees directly involved in the conduct of the trial

Additional Module 2 Inclusion Criteria:

  1. Women only
  2. Pre- or peri-menopausal women must have initiated LHRHa at least 28 days prior to first dose of CT7001/placebo
  3. Histologically-confirmed, metastatic or locally advanced, ER+ve and/or PGR+ve and HER2-ve breast cancer
  4. Part A only: Disease measurable by RECIST v1.1
  5. Documented objective disease progression while on, or within 6 months after the end of, the most recent therapy
  6. Must have received an aromatase inhibitor together with a CDK4/6 inhibitor in the same line of therapy for locally advanced or metastatic disease or for treatment of early breast cancer if the disease-free interval was <12 months.
  7. For Part B only: patients must have received at least 6 months clinical benefit with the CDK4/6 as a line of therapy immediately preceding study entry. Patients who received CDK4/6 inhibitor < 6 months due to tolerability issues when at least 6 months aromatase inhibitor was received.
  8. Ability to receive intramuscular injections.

Additional Module 2 Exclusion Criteria:

  1. Prior therapy with fulvestrant
  2. More than 2 lines of endocrine treatment for locally advanced or metastatic disease
  3. Part A Only: Prior treatment with more than one line of cytotoxic chemotherapy for locally advanced or metastatic breast cancer.
  4. Part B Only: Prior treatment with cytotoxic chemotherapy for locally advanced or metastatic breast cancer or treatment with a mammalian target of rapamycin (mTOR) inhibitor including, but not limited to, everolimus.
  5. Patients with liver metastasis will be limited to approximately 30-40% of the enrolled patients. l
  6. Known hypersensitivity to CT7001, fulvestrant or any excipient of the investigational products
  7. Patients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Carrick employees directly involved in the conduct of the trial

Additional Module 4 Inclusion Criteria:

  1. Patients must be able to eat a high-fat meal, as provided by the study site, within a 30-minute period
  2. Histological, radiological or cytological confirmation of an advanced non-haematological malignancy not considered to be appropriate for further standard treatment

Additional Module 4 Exclusion Criteria:

1. Patients who were unable to fast for at least 10 hours

Additional Module 6 Inclusion Criteria:

1. Histological, radiological or cytological confirmation of an advanced non- haematological malignancy not considered to be appropriate for further standard treatment.

Additional Module 6 Exclusion Criteria:

  1. Any concurrent gastrointestinal conditions, not covered in Core Protocol Exclusion Criteria #4
  2. Patients whom has received an agent that increases gastric pH (i.e. proton pump inhibitors (PPI), H2 antagonists) within 2 days or 5 half-lives, whichever is shorter, prior to PK Period Day 1.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03363893


Locations
Show Show 23 study locations
Sponsors and Collaborators
Carrick Therapeutics Limited
Investigators
Layout table for investigator information
Principal Investigator: Matthew Krebs, MBChB PhD The Christie Hospital, Manchester, UK
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Carrick Therapeutics Limited
ClinicalTrials.gov Identifier: NCT03363893    
Other Study ID Numbers: CT7001_001
2017-002026-20 ( EudraCT Number )
First Posted: December 6, 2017    Key Record Dates
Last Update Posted: February 9, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Carrick Therapeutics Limited:
Neoplasms
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Fulvestrant
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
 Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs